TIAA Trust National Association Acquires 656 Shares of Edwards Lifesciences Co. (NYSE:EW)

TIAA Trust National Association increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,943 shares of the medical research company’s stock after purchasing an additional 656 shares during the quarter. TIAA Trust National Association’s holdings in Edwards Lifesciences were worth $810,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Larson Financial Group LLC lifted its holdings in shares of Edwards Lifesciences by 199.1% in the third quarter. Larson Financial Group LLC now owns 4,391 shares of the medical research company’s stock worth $290,000 after buying an additional 2,923 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Edwards Lifesciences in the 3rd quarter valued at $825,000. Private Trust Co. NA lifted its stake in Edwards Lifesciences by 8.6% in the 3rd quarter. Private Trust Co. NA now owns 2,931 shares of the medical research company’s stock worth $193,000 after purchasing an additional 233 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of Edwards Lifesciences by 20.5% during the 3rd quarter. Townsquare Capital LLC now owns 5,208 shares of the medical research company’s stock valued at $344,000 after purchasing an additional 886 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its position in shares of Edwards Lifesciences by 6.0% during the third quarter. Glenmede Trust Co. NA now owns 381,168 shares of the medical research company’s stock valued at $25,153,000 after purchasing an additional 21,505 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $71.17 on Friday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock’s fifty day moving average price is $71.47 and its 200-day moving average price is $70.46. The firm has a market cap of $41.84 billion, a P/E ratio of 10.21, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on EW. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $79.95.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares of the company’s stock, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock worth $4,513,064 over the last 90 days. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.